PYXS Nasdaq· Pyxis Oncology Inc.
FundamentalsNews digest Peer analysis
PYXS Nasdaq· Pyxis Oncology Inc.
Earnings report Q3 2023

Pyxis Oncology Reports Decreased Revenue in Latest Quarter

Segments of revenue

Pyxis Oncology, Inc. reported a decrease in revenue for the latest quarter. The company's revenue is primarily derived from two segments: research and development (R&D) and general and administrative (G&A) expenses.

In the three months ended September 30, 2023, Pyxis Oncology's R&D expenses amounted to $14.69 million, compared to $19.03 million in the same period last year. This represents a decrease of approximately 23%. Similarly, G&A expenses for the quarter were $10.67 million, slightly higher than the $9.36 million reported in the previous year's quarter.


Despite the decrease in revenue, Pyxis Oncology's management highlighted several strengths in their financial performance. The company continues to invest significantly in research and development, which is crucial for the development of innovative oncology treatments. The decrease in R&D expenses compared to the previous year can be attributed to the successful completion of certain projects or cost-saving measures implemented by the company.


The decrease in revenue for Pyxis Oncology raises concerns about the company's ability to generate sufficient funds for its operations. The decline in R&D expenses may indicate a slowdown in the development of new treatments or a reduction in the company's pipeline. Additionally, the increase in G&A expenses suggests higher administrative costs, which could impact the company's overall profitability.


It is worth noting that Pyxis Oncology reported a net loss of $23.05 million for the quarter, compared to a net loss of $27.67 million in the same period last year. The decrease in net loss can be attributed to the higher interest and investment income of $1.71 million, compared to $0.72 million in the previous year's quarter. This increase in other income partially offset the decline in revenue.


Pyxis Oncology, Inc. faced challenges in the latest quarter with a decrease in revenue. The company's R&D expenses decreased, indicating potential completion of projects or cost-saving measures. However, the increase in G&A expenses and the overall net loss raise concerns about the company's financial performance. Pyxis Oncology will need to address these challenges and focus on generating sustainable revenue to support its operations and future growth.

Source documents

Form 10-Q  filed on Nov 07, 2023
10 pages scanned

Reference data

Company financials Q3 revenue 0
Analyst estimates Q3 EPS missed by -34.87%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.